NZ 597666 Disclosed is the use of an a fucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, for the manufacture of a medicament for the treatment of cancer in combination with bendamustine, wherein said antibody is a humanised B-Ly1 antibody, and the humanised B-Ly1 antibody is characterised in comprising an amino acid sequence of the variable region of the heavy chain (VH) of SEQ ID NO: 7, and in comprising an amino acid sequence of the variable region of the light chain (VL) of SEQ ID NO: 20 as defined in the complete specification. The disclosed humanised B-Ly1 antibody is administered in a dosage of 800 to 1200 mg on day 1, 8, 15 of a 6-week-dosage-cycle and then in a dosage of 800 to 1200 mg on day 1 of up to five 4-week-dosage-cycles, and bendamustine is administered in a dosage of 80 mg/m2 to 110 mg/m2 on day 1 and 2 of up to six 4-week-dosage-cycles.
